Aurora Cannabis Inc. (NASDAQ:ACB) Q1 2025 Results Conference Call August 7, 2024 8:00 AM ET

Company Participants

Kevin Niland - Director, Strategic Finance and IR
Miguel Martin - Chief Executive Officer
Simona King - Chief Financial Officer

Conference Call Participants

Pablo Zuanic - Zuanic & Associates

Operator

Hello, everyone, and welcome to the Aurora Cannabis Incorporated Fiscal First Quarter 2025 Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] This conference call is being recorded today, Wednesday, August 7, 2024. [Operator Instructions].

I will now turn the conference over to your host, Kevin Niland, Director, Strategic Finance and Investor Relations. Please go ahead.

Kevin Niland

Hello, everyone, and thank you for joining us. On the line with me are Miguel Martin, CEO; and Simona King, CFO. This morning, Aurora issued a news release announcing our fiscal 2025 first quarter financial results. Financial statements, MD&A and this news releases are available on our IR website can also be accessed via SEDAR+ and EDGAR.

For today's conference call, listeners are reminded that certain matters could constitute forward-looking statements and are subject to risks and uncertainties related to our future financial or business performance. Actual results could differ materially from those anticipated in those forward-looking statements.

The risk factors that may affect actual results are detailed in our annual information form and other periodic filings and registration statements. These documents may similar be access via SEDAR+ and EDGAR. Following prepared remarks by Miguel and Simona, we'll conduct a question-and-answer session with our covering analysts.

With that, I'll turn the call over to Miguel. Please go ahead.

Miguel Martin

Thank you, Kevin. Having reported our previous fiscal quarter just a few weeks ago, we will be relatively brief in our prepared remarks. Q1 2025 was a milestone period for Aurora, and we cannot be more pleased with the results that we'll be sharing with you today. We grew our top line to $83.4 million, which included record revenue in Canadian medical cannabis, international medical cannabis implant propagation during VIVO's seasonally strongest quarter.

We take great pride in Aurora being the global medical cannabis leader within nationally legal markets. This enables us to capitalize on rapidly evolving opportunities in countries around the world. And through our investment in VIVO two years ago, we have also become an important player within North America's controlled environment agricultural industry. This generates a steady, predictable financial performance on a seasonal cadence, and we foresee more value creation through an acceleration of VIVO's business plan.